Image For Activity Cover
Focus on Ischemic and Valvular Heart Disease: Debates on Best Outcomes with Percutaneous vs Surgical Interventions
General Description
HFSA Heart Failure Seminar: Focus on Ischemic and Valvular Heart Disease
Debates on Best Outcomes with Percutaneous vs Surgical Interventions

Original Seminar Date:  February 2, 2023
Product Expiration Date: February 9, 2024

This seminar will feature heart failure experts discussing percutaneous and surgical interven-tions. Despite the advances in medical therapy, with growing benefit from the “4 pillars” of guide-line directed medical therapy (GDMT), subsets of patients derive signification improvement in out-comes utilizing advanced percutaneous and surgical interventions via improvement in coronary flow, valvular function, and pump function.
Target Audience
This program is intended for physicians, nurses, nurse practitioners, pharmacists, and advanced practice professionals that provide care to patients with heart failure.
Agenda
  • Welcome - F. Vaghaiwalla Mody
  • Debate I: Ischemic Heart Disease - PCI vs CABG    
    • Case Presentation - V. Blumer
    • PCI - R. Mehran
    • CABG - A. Ardehali
  • Debate II: Mitral Valve Disease - Mitral Clip TEER vs Surgical MVR    
    • Case Presentation - V. Blumer
    • Mitral Clip - M. Calfon Press
    • Surgical MVR - V. Chan
  • Debate III: Aortic Stenosis - TAVR vs Surgical AVR    
    • Case Presentation - V. Blumer
    • TAVR - R. Makkar
    • Surgical AVR - M. Mack
  • Closing Remarks - F. Vaghaiwalla Mody
Learning Objectives and Knowledge Gaps
Learning Objectives
  • Review the current data on the options for coronary revascularization, when, how, and who benefits for it
  • To review the current indications and risk regarding valvular intervention in heart fail-ure, and the data that support surgical vs. percutaneous valvular intervention
Knowledge Gaps
  • To identify clinical criteria in heart failure patients that benefit from advanced thera-pies and refer in a timely fashion
  • To gain knowledge of the indications and contraindications associated with percuta-neous and surgical coronary and valvular interventions
  • To gain knowledge of potential complications associated with interventional and sur-gical interventions.
Program Planners
Jennifer Cook, MD – University of Cincinnati, OH
Freny Vaghaiwalla Mody, MD – VA Greater Los Angeles Healthcare System
Nelly Aghili, DNP, APRN, AGACNP-BC - University of California
Faculty
Moderator(s)
  • Freny Vaghaiwalla Mody, MD – VA Greater Los Angeles Healthcare System
  • Fellow/Early Career Moderator: Vanessa Blumer, MD – Cleveland Clinic

Speaker(s)
  • Abbas Ardehali, MD – University of California, Los Angeles
  • Marcella Calfon Press MD, PhD – University of California, Los Angeles
  • Vincent Chan, MD, MPH – University of Ottawa Heart Institute
  • Michael Mack, MD – Baylor Scott & White Health
  • Raj Makkar, MD – Cedars-Sinai
  • Roxana Mehran, MD – Mount Sinai Hospital
Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

  • Abbas Ardehali, MD
  • Nelly Aghili, DNP, APRN, AGACNP-BC
  • Vanessa Blumer, MD
  • Vincent Chan, MD
  • Jennifer Cook, MD
  • Marcella Calfon Press MD, PhD

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
  • Michael Mack, MD – Trial Co-PI: Abbott, Edwards Lifesciences; Study Chair: Medtronic Raj Makkar, MD – Research Grant: Abbott, Edwards Lifesciences, Boston Scientific; Consultant: Cordis, Medtronic
  • Roxana Mehran, MD – Institutional Research Payment: Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filter-lex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtel-ligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vi-vasure, Zoll; Consultant: Cine-Med Research, Ionis Phar-maceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Other: Scientific Advisory Board for AMA, ACC (BOT Member, SC Member CTR Program), SCAI (Women in Innovations Commit-tee Member), JAMA Cardiology Associate Editor; Faculty CRF (no fee).
  • Freny Vaghaiwalla Mody, MD – Research: National Institutes of Health, Merck, LivaNova, Novartis

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Accreditation Statement
JA Artwork6
Accreditation Statement In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity. This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Supporters
The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support the Heart Failure Seminar: Focus on Ischemic and Valvular Heart Disease: Abbott, Medtronic
Summary
Availability: Retired
Cost: Member: $49.00
Non-Member: $89.00
Credit Offered:
No Credit Offered
Recommended
Powered by Oasis.